Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clini...
Q1 2026
May 13, 2026
FY 2025
Mar 6, 2026
Q4 2025
Q3 2025
Nov 6, 2025
Q2 2025
Aug 12, 2025